| pubmed-article:21541225 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21541225 | lifeskim:mentions | umls-concept:C0521026 | lld:lifeskim |
| pubmed-article:21541225 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21541225 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21541225 | lifeskim:mentions | umls-concept:C0542559 | lld:lifeskim |
| pubmed-article:21541225 | lifeskim:mentions | umls-concept:C0243161 | lld:lifeskim |
| pubmed-article:21541225 | lifeskim:mentions | umls-concept:C0231174 | lld:lifeskim |
| pubmed-article:21541225 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:21541225 | pubmed:dateCreated | 2011-5-4 | lld:pubmed |
| pubmed-article:21541225 | pubmed:abstractText | Our objective was to evaluate outcomes in patients with sustained viral suppression compared to those with episodes of viremia. Methods. In a prospective cohort of patients started on ART in Uganda and followed for 48 months, patients were categorized according to viral load (VL): (1) sustained-suppression: (VL ?1,000 copies/mL) (2) VL 1,001-10,000, or (3) VL >10,000. Results. Fifty-Three (11.2%) and 84 (17.8%) patients had a first episode of intermediate and high viremia, respectively. Patients with sustained suppression had better CD4+ T cell count increases over time compared to viremic patients (P < .001). The majority of patients with viremia achieved viral suppression when the measurement was repeated. Only 39.6% of patients with intermediate and 19.1% with high viremia eventually needed to be switched to second line (P = .008). Conclusions. The use of at least one repeat measurement rather than a single VL measurement could avert from 60% to 80% of unnecessary switches. | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21541225 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21541225 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:21541225 | pubmed:issn | 2090-1259 | lld:pubmed |
| pubmed-article:21541225 | pubmed:author | pubmed-author:ManabeYukari... | lld:pubmed |
| pubmed-article:21541225 | pubmed:author | pubmed-author:KamyaMoses... | lld:pubmed |
| pubmed-article:21541225 | pubmed:author | pubmed-author:CastelnuovoBa... | lld:pubmed |
| pubmed-article:21541225 | pubmed:author | pubmed-author:SempaJosephJ | lld:pubmed |
| pubmed-article:21541225 | pubmed:author | pubmed-author:AgnesKiragga... | lld:pubmed |
| pubmed-article:21541225 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21541225 | pubmed:volume | 2011 | lld:pubmed |
| pubmed-article:21541225 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21541225 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21541225 | pubmed:pagination | 736938 | lld:pubmed |
| pubmed-article:21541225 | pubmed:dateRevised | 2011-7-28 | lld:pubmed |
| pubmed-article:21541225 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21541225 | pubmed:articleTitle | Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings. | lld:pubmed |
| pubmed-article:21541225 | pubmed:affiliation | Infectious Diseases Institute, Makerere University, Mulago Hospital Complex, P.O. Box 22418, Kampala, Uganda. | lld:pubmed |
| pubmed-article:21541225 | pubmed:publicationType | Journal Article | lld:pubmed |
